The FDA has granted an accelerated approval for Otarmeni (lunsotogene parvec-cwha), the first gene therapy to treat patients ...
Approval in severe-to-profound and profound OTOF -related hearing loss is based on pivotal results of the CHORD trial demonstrating 80% of ...
The FDA granted accelerated approval to lunsotogene parvec (Otarmeni) as the first gene therapy for genetic hearing loss, the ...
Supported by the CHORD trial, this AAV vector-based therapy delivers a working copy of the OTOF gene and restores otoferlin protein production.
Crack open any biology textbook, and you’ll find tidy diagrams, clean labels, and plenty of comforting facts about the human ...
The FDA has granted accelerated approval to lunsotogene parvec-cwha (Otarmeni), an adeno-associated virus (AAV) vector–based ...
Morning Overview on MSN
Gene therapy restored hearing in 90% with OTOF deafness, study says
A single injection into the inner ear restored functional hearing in 90% of people born deaf because of mutations in the OTOF ...
This is a useful study that seeks to elucidate the molecular mechanisms underlying spinal motor circuit assembly. The authors demonstrate that loss of Onecut transcription factors in spinal motor ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results